Monday, March 16, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Beijing 2022: China readies for Winter Olympics as pressure grows

For the first time since the original coronavirus outbreak closed China’s borders, the country is preparing to allow foreigners to enter again in large numbers for the winter Olympics next February.

This had not seemed like it would pose much of a problem. People had become accustomed to life without many Covid restrictions, with authorities stamping out each outbreak of the virus as it came along.

But everything changed when the highly-contagious Delta variant made its way into China via an airport in the eastern city of Nanjing.

In July and August it quickly spread to dozens of cities and towns, threatening China’s status of having the virus controlled.

As they had before, authorities pursued a goal of full elimination.

The strategy is always the same. Phone app health clearance is implemented in order to enter public buildings, track and trace methods go into overdrive and, as infected people are identified, their housing estates placed into lockdown.

Source: BBC

https://www.bbc.com/news/world-asia-china-58196467

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!